<![CDATA[TauRx Pharmaceuticals Ltd. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=43612>Wed, 29 Apr 2026 12:14:04 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease]]>https://www.newswire.co.kr/newsRead.php?no=992588Mon, 01 Jul 2024 16:35:08 +0900<![CDATA[Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial]]>https://www.newswire.co.kr/newsRead.php?no=985568Fri, 08 Mar 2024 09:40:00 +0900<![CDATA[하이드로메틸티오닌 메실레이트의 2년 지속된 인지적 이점, 타우Rx의 LUCIDITY 임상시험에서 나타나]]>https://www.newswire.co.kr/newsRead.php?no=985572Fri, 08 Mar 2024 09:40:00 +0900<![CDATA[TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March]]>https://www.newswire.co.kr/newsRead.php?no=983828Mon, 05 Feb 2024 17:40:00 +0900<![CDATA[타우Rx, 3월 AD/PD™ 2024 콘퍼런스에서 알츠하이머병 치료제 HMTM에 대한 제3상 시험 2년 데이터 발표 예정]]>https://www.newswire.co.kr/newsRead.php?no=983830Mon, 05 Feb 2024 17:40:00 +0900<![CDATA[TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)]]>https://www.newswire.co.kr/newsRead.php?no=970678Mon, 17 Jul 2023 09:30:00 +0900<![CDATA[TauRx의 HMTM, 알츠하이머병의 신경 퇴행을 현저히 감소시키는 것을 입증]]>https://www.newswire.co.kr/newsRead.php?no=970679Mon, 17 Jul 2023 09:30:00 +0900